药物利用评价和药物利用评估法评价我院慢性乙型肝炎住院患者保肝药的使用情况
发布时间：2018-11-07 12:44
【摘要】：目的评价嘉兴市第一医院慢性乙型肝炎住院患者保肝药的用药情况及合理性,为临床合理用药提供参考。方法采用药物利用评价(DUR)和药物利用评估(DUE)法,对该院慢性乙型肝炎住院患者使用保肝药的药物利用指数(DUI)、药物应用情况、治疗过程监测及临床治疗效果进行分析。结果 97例患者共使用保肝药17个品种、21个品规,用药频度前3位的药物分别为多烯磷脂酰胆碱注射液、注射用丁二磺酸腺苷蛋氨酸和注射用复方甘草酸苷。5个品规药物的DUI1,13个品规的DUI=1,3个品规的DUI1。一联、二联、三联和四联用药的构成比分别为30.93%(30/97)、46.39%(45/97)、17.53%(17/97)和5.15%(5/97),对应患者肝功能恢复或好转构成比依次为70.00%(21/30)、91.11%(41/45)、82.35%(14/17)和60.00%(3/5)。研究对象均符合病原学分型及临床分期,仅3.09%(3/97)的病例确定了病理学分期。97例患者均有肝功能异常现象,肝功能监测率达100.00%(97/97),93例患者经抗炎保肝等治疗后临床症状得到改善,79例患者肝功能恢复正常。结论联合DUR和DUE法可以更全面地评价慢性乙型肝炎患者的用药情况。该院慢性乙型肝炎住院患者保肝药用药基本合理,二联用药保肝治疗效果最好。
[Abstract]:Objective to evaluate the usage and rationality of liver protective drugs in patients with chronic hepatitis B (CHB) in Jiaxing first Hospital, and to provide reference for rational use of drugs in clinic. Methods Drug utilization evaluation (DUR) and drug utilization assessment (DUE) were used to evaluate the drug utilization index (DUI),) of patients with chronic hepatitis B in our hospital. The therapeutic process monitoring and clinical treatment effect were analyzed. Results in 97 patients, 17 kinds of hepatoprotective drugs were used, 21 drugs were used, and the top 3 drugs were polyenylphosphatidylcholine injection. Adenosylmethionine butyldisulfonic acid for injection and compound glycyrrhizin for injection. DUI1, of 5 drugs, DUI=1, of 13 products and DUI1. of 3 products The constituent ratios of one, two, three and four drugs were 30.93% (30 / 97), 46.39% (45 / 97), 17.53% (17 / 97) and 5.15% (5 / 97), respectively. The proportion of recovery or improvement of liver function was 70.00% (21 / 30), 91.11% (41 / 45), 82.35% (14 / 17) and 60.00% (3 / 5) respectively. The pathological staging was confirmed in only 3.09% (3 / 97) of the patients. The abnormal liver function was found in 97 patients, and the monitoring rate of liver function was 100.00% (97 / 97). The clinical symptoms of 93 patients were improved after anti-inflammatory therapy and liver preservation therapy, and 79 patients returned to normal liver function. Conclusion the combination of DUR and DUE can more comprehensively evaluate the drug use in patients with chronic hepatitis B. The liver protection drugs used in the inpatients with chronic hepatitis B in our hospital were basically reasonable, and the combined therapy was the best.
【作者单位】： 嘉兴市第一医院药学部;嘉兴市第一医院感染科;
【基金】：浙江省药学会医院药学专项科研资助项目(2014-ZYY29)
【分类号】：R512.62
[Abstract]:Objective to evaluate the usage and rationality of liver protective drugs in patients with chronic hepatitis B (CHB) in Jiaxing first Hospital, and to provide reference for rational use of drugs in clinic. Methods Drug utilization evaluation (DUR) and drug utilization assessment (DUE) were used to evaluate the drug utilization index (DUI),) of patients with chronic hepatitis B in our hospital. The therapeutic process monitoring and clinical treatment effect were analyzed. Results in 97 patients, 17 kinds of hepatoprotective drugs were used, 21 drugs were used, and the top 3 drugs were polyenylphosphatidylcholine injection. Adenosylmethionine butyldisulfonic acid for injection and compound glycyrrhizin for injection. DUI1, of 5 drugs, DUI=1, of 13 products and DUI1. of 3 products The constituent ratios of one, two, three and four drugs were 30.93% (30 / 97), 46.39% (45 / 97), 17.53% (17 / 97) and 5.15% (5 / 97), respectively. The proportion of recovery or improvement of liver function was 70.00% (21 / 30), 91.11% (41 / 45), 82.35% (14 / 17) and 60.00% (3 / 5) respectively. The pathological staging was confirmed in only 3.09% (3 / 97) of the patients. The abnormal liver function was found in 97 patients, and the monitoring rate of liver function was 100.00% (97 / 97). The clinical symptoms of 93 patients were improved after anti-inflammatory therapy and liver preservation therapy, and 79 patients returned to normal liver function. Conclusion the combination of DUR and DUE can more comprehensively evaluate the drug use in patients with chronic hepatitis B. The liver protection drugs used in the inpatients with chronic hepatitis B in our hospital were basically reasonable, and the combined therapy was the best.
【作者单位】： 嘉兴市第一医院药学部;嘉兴市第一医院感染科;
【基金】：浙江省药学会医院药学专项科研资助项目(2014-ZYY29)
【分类号】：R512.62
【相似文献】
相关期刊论文 前10条
1 邹豪，陈盛新;药物利用评价的内涵及方法[J];药学实践杂志;1996年05期
2 赖琪,胡明,蒲剑,吴蓬;药物利用评价与医院质量保证[J];中国药师;2001年06期
3 刘喜军,魏水易;药物利用评价的现状与发展趋势[J];中国医院用药评价与分析;2003年06期
4 吴廷s，
本文编号：2316413
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/2316413.html
最近更新
教材专著
